Lifetime cancer risk with progestin and estrogen oral contraceptives and hormone therapy
Grant, E.C.G.
American Journal of Obstetrics and Gynecology 217(2): 232-233
2017
ISSN/ISBN: 1097-6868 PMID: 28502754 DOI: 10.1016/j.ajog.2017.05.005Document Number: 664902
Document emailed within 0-6 h
Related Documents
Schildkraut, J.M.; Calingaert, B.; Marchbanks, P.A.; Moorman, P.G.; Rodriguez, G.C. 2002: Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk Journal of the National Cancer Institute 94(1): 32-38Birch-Johansen, F.; Jensen, A.; Olesen, A.B.; Christensen, J.; Tjønneland, A.; Kjær, S.K. 2012: Does hormone replacement therapy and use of oral contraceptives increase the risk of non-melanoma skin cancer? Cancer Causes and Control: Ccc 23(2): 379-388
Faber, M.T.; Jensen, A.; Frederiksen, K.; Glud, E.; Høgdall, E.; Høgdall, C.; Blaakaer, J.; Kjaer, S.K. 2013: Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer Cancer Causes and Control: Ccc 24(12): 2197-2206
Persson, I. 1996: Cancer risk in women receiving estrogen-progestin replacement therapy Maturitas 23(Suppl): S37-S45
Bono, Y.; Kyo, S.; Kiyono, T.; Mizumoto, Y.; Nakamura, M.; Maida, Y.; Takakura, M.; Fujiwara, H. 2014: Concurrent estrogen action was essential for maximal progestin effect in oral contraceptives Fertility and Sterility 101(5): 1337-1343
Shapiro, S.; Rosenberg, L.; Hoffman, M.; Kelly, J.P.; Cooper, D.D.; Carrara, H.; Denny, L.E.; du Toit, G.; Allan, B.R.; Stander, I.A.; Williamson, A-Lise. 2003: Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) Cancer Causes and Control: Ccc 14(5): 485-495
Shapiro, S.; Rosenberg, L.; Hoffman, M.; Kelly, J.P.; Cooper, D.D.; Carrara, H.; Denny, L.E.; du Toit, G.; Allan, B.R.; Stander, I.A.; Williamson, A-Lise. 2003: Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) Cancer Causes and Control: Ccc 14(5): 485-495
Brändstedt, J.; Wangefjord, S.; Nodin, Börn.; Eberhard, J.; Jirström, K.; Manjer, J. 2014: Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability Bmc Cancer 14: 371
Schlesselman, J.J.; Stadel, B.V.; Murray, P.; Lai, S.H. 1987: Breast cancer risk in relation to type of estrogen contained in oral contraceptives Contraception 36(6): 595-613
Doran, M.F.; Crowson, C.S.; O'Fallon, W.Michael.; Gabriel, S.E. 2004: The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study Journal of Rheumatology 31(2): 207-213
Carranza-Lira, S.án.; MacGregor-Gooch, A.L.; Saráchaga-Osterwalder, M. 2004: Mood modifications with raloxifene and continuous combined estrogen plus progestin hormone therapy International Journal of Fertility and Women's Medicine 49(3): 120-122
Fentiman, I.S. 2002: 20. Oral contraceptives, hormone replacement therapy and breast cancer International Journal of Clinical Practice 56(10): 755-759
Corenblum, B.; Donovan, L. 1993: The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia Fertility and Sterility 59(3): 671-673
Xing, S.; Wu, Y.; Liu, J.; Xu, R.; Zhang, Z.; Wang, Y. 2003: A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin Chinese Medical Journal 116(4): 584-587
Li, L.; Ji, J.; Wang, J.-B.; Niyazi, M.; Qiao, Y.-L.; Boffetta, P. 2012: Attributable causes of breast cancer and ovarian cancer in china: reproductive factors, oral contraceptives and hormone replacement therapy Chinese Journal of Cancer Research 24(1): 9-17
Santen, R.J.; Pinkerton, J.; McCartney, C.; Petroni, G.R. 2001: Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy Journal of Clinical Endocrinology and Metabolism 86(1): 16-23
Glaser, A.N. 2000: Estrogen-progestin replacement and risk of breast cancer JAMA 284(6): 692; Author Reply 693-4
Stephens, M.B. 2000: Estrogen-progestin increases breast cancer risk Journal of Family Practice 49(4): 301-302
Lagergren, K.; Lagergren, J.; Brusselaers, N. 2015: Hormone Replacement Therapy and Oral Contraceptives and Risk of Oesophageal Adenocarcinoma: a Systematic Review and Meta-analysis International Journal of Epidemiology 44(Suppl_1): I187-I188
Magnusson, C.; Weiderpass, E. 2001: Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer Lakartidningen 98(5): 418-421